A Cost-effectiveness Study of Intravenous Immunoglobulin in Childhood Idiopathic Thrombocytopenia Purpura Patients with Life-Threatening BleedingSRUAMSIRI, Rosarin; DILOKTHORNSAKUL, Piyameth; PRATOOMSOOT, Chayanin et al.PharmacoEconomics (Auckland). 2014, Vol 32, Num 8, pp 801-813, issn 1170-7690, 13 p.Article

Can the Real Opportunity Cost Stand Up: Displaced Services, the Straw Man Outside the RoomECKERMANN, Simon; PEKARSKY, Brita.PharmacoEconomics (Auckland). 2014, Vol 32, Num 4, pp 319-325, issn 1170-7690, 7 p.Article

Discrete Choice Experiments in Health Economics: A Review of the LiteratureCLARK, Michael D; DETERMANN, Domino; PETROU, Stavros et al.PharmacoEconomics (Auckland). 2014, Vol 32, Num 9, pp 883-902, issn 1170-7690, 20 p.Article

Fibromyalgia: Disease Synopsis, Medication Cost Effectiveness and Economic BurdenSKAER, Tracy L.PharmacoEconomics (Auckland). 2014, Vol 32, Num 5, pp 457-466, issn 1170-7690, 10 p.Article

HTA Agencies Facing Model Biases: The Case of Type 2 DiabetesRAIMOND, Véronique; JOSSELIN, Jean-Michel; ROCHAIX, Lise et al.PharmacoEconomics (Auckland). 2014, Vol 32, Num 9, pp 825-839, issn 1170-7690, 15 p.Article

The Burden of Disease in Rheumatoid ArthritisUHLIG, Till; MOE, Rikke H; KVIEN, Tore K et al.PharmacoEconomics (Auckland). 2014, Vol 32, Num 9, pp 841-851, issn 1170-7690, 11 p.Article

The Economic Burden of Head and Neck Cancer: A Systematic Literature ReviewWISSINGER, Erika; GRIEBSCH, Ingolf; LUNGERSHAUSEN, Juliane et al.PharmacoEconomics (Auckland). 2014, Vol 32, Num 9, pp 865-882, issn 1170-7690, 18 p.Article

Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied?MATTER-WALSTRA, Klazien; KLINGBIEL, Dirk; SZUCS, Thomas et al.PharmacoEconomics (Auckland). 2014, Vol 32, Num 6, pp 591-599, issn 1170-7690, 9 p.Article

When to Use Discrete Event Simulation (DES) for the Economic Evaluation of Health Technologies? A Review and Critique of the Costs and Benefits of DESKARNON, Jonathan; HOSSEIN HAJI ALI AFZALI.PharmacoEconomics (Auckland). 2014, Vol 32, Num 6, pp 547-558, issn 1170-7690, 12 p.Article

A Review of the Economic Burden of Glioblastoma and the Cost Effectiveness of Pharmacologic TreatmentsMESSALI, Andrew; VILLACORTA, Reginald; HAY, Joel W et al.PharmacoEconomics (Auckland). 2014, Vol 32, Num 12, pp 1201-1212, issn 1170-7690, 12 p.Article

Cost-Utility Analysis of Chemotherapy Regimens in Elderly Patients with Stage III Colon CancerLAIRSON, David R; PARIKH, Rohan C; CORMIER, Janice N et al.PharmacoEconomics (Auckland). 2014, Vol 32, Num 10, pp 1005-1013, issn 1170-7690, 9 p.Article

Modelling Outcomes of Complex Treatment Strategies Following a Clinical Guideline for Treatment Decisions in Patients with Rheumatoid ArthritisTRAN-DUY, An; BOONEN, Annelies; KIEVIT, Wietske et al.PharmacoEconomics (Auckland). 2014, Vol 32, Num 10, pp 1015-1028, issn 1170-7690, 14 p.Article

Through a Glass Darkly: Economics and Personalised MedicineHAYCOX, Alan; PIRMOHAMED, Munir; MCLEOD, Claire et al.PharmacoEconomics (Auckland). 2014, Vol 32, Num 11, pp 1055-1061, issn 1170-7690, 7 p.Article

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) StatementHUSEREAU, Don; DRUMMOND, Michael; PETROU, Stavros et al.PharmacoEconomics (Auckland). 2013, Vol 31, Num 5, pp 361-367, issn 1170-7690, 7 p.Article

A Person Trade-Off Study to Estimate Age-Related Weights for Health Gains in Economic EvaluationPETROU, Stavros; KANDALA, Ngianga-Bakwin; ROBINSON, Angela et al.PharmacoEconomics (Auckland). 2013, Vol 31, Num 10, pp 893-907, issn 1170-7690, 15 p.Article

Bivalirudin for the Treatment of ST-Segment Elevation Myocardial Infarction: A NICE Single Technology AppraisalSIMPSON, E. L; FITZGERALD, P; EVANS, P et al.PharmacoEconomics (Auckland). 2013, Vol 31, Num 4, pp 269-275, issn 1170-7690, 7 p.Article

Constructing Indirect Utility Models: Some Observations on the Principles and Practice of Mapping to Obtain Health State UtilitiesMCCABE, Christopher; EDLIN, Richard; MEADS, David et al.PharmacoEconomics (Auckland). 2013, Vol 31, Num 8, pp 635-641, issn 1170-7690, 7 p.Article

Cost Effectiveness of Antiarrhythmic Medications in Patients Suffering from Atrial FibrillationBRÜGGENJÜRGEN, Bernd; KOHLER, Stefan; EZZAT, Nadja et al.PharmacoEconomics (Auckland). 2013, Vol 31, Num 3, pp 195-213, issn 1170-7690, 19 p.Article

Cost Effectiveness of First-Line Oral Antiviral Therapies for Chronic Hepatitis B: A Systematic ReviewBUTI, Maria; OYAGÜEZ, Itziar; LOZANO, Virginia et al.PharmacoEconomics (Auckland). 2013, Vol 31, Num 1, pp 63-75, issn 1170-7690, 13 p.Article

Costs of Parkinson's Disease in a Privately Insured PopulationJOHNSON, Scott J; KALTENBOECK, Anna; DIENER, Melissa et al.PharmacoEconomics (Auckland). 2013, Vol 31, Num 9, pp 799-806, issn 1170-7690, 8 p.Article

Disutility of Illness for Caregivers and Families: A Systematic Review of the LiteratureWITTENBERG, Eve; PROSSER, Lisa A.PharmacoEconomics (Auckland). 2013, Vol 31, Num 6, pp 489-500, issn 1170-7690, 12 p.Article

Good Practice Guidelines for the use of Statistical Regression Models in Economic EvaluationsKEARNS, Ben; ARA, Roberta; WAILOO, Allan et al.PharmacoEconomics (Auckland). 2013, Vol 31, Num 8, pp 643-652, issn 1170-7690, 10 p.Article

Improving Clinical Reality in Chronic Obstructive Pulmonary Disease Economic Modelling: Development and Validation of a Micro-Simulation ApproachASUKAI, Yumi; BALDWIN, Michael; FONSECA, Tiago et al.PharmacoEconomics (Auckland). 2013, Vol 31, Num 2, pp 151-161, issn 1170-7690, 11 p.Article

Operationalizing Value-Based Pricing of Medicines: A Taxonomy of ApproachesSUSSEX, Jon; TOWSE, Adrian; DEVLIN, Nancy et al.PharmacoEconomics (Auckland). 2013, Vol 31, Num 1, pp 1-10, issn 1170-7690, 10 p.Article

Productivity Costs in Economic Evaluations: Past, Present, FutureKROL, Marieke; BROUWER, Werner; RUTTEN, Frans et al.PharmacoEconomics (Auckland). 2013, Vol 31, Num 7, pp 537-549, issn 1170-7690, 13 p.Article